Stratec SE
XETRA:SBS
Intrinsic Value
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. [ Read More ]
The intrinsic value of one SBS stock under the Base Case scenario is 71.24 EUR. Compared to the current market price of 40.2 EUR, Stratec SE is Undervalued by 44%.
Valuation Backtest
Stratec SE
Run backtest to discover the historical profit from buying and selling SBS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Stratec SE
Current Assets | 222.4m |
Cash & Short-Term Investments | 20.1m |
Receivables | 62.5m |
Other Current Assets | 139.8m |
Non-Current Assets | 220.7m |
Long-Term Investments | 3.5m |
PP&E | 81.4m |
Intangibles | 119.4m |
Other Non-Current Assets | 16.4m |
Current Liabilities | 97.7m |
Accounts Payable | 14.3m |
Other Current Liabilities | 83.4m |
Non-Current Liabilities | 119.6m |
Long-Term Debt | 95.1m |
Other Non-Current Liabilities | 24.4m |
Earnings Waterfall
Stratec SE
Revenue
|
254.7m
EUR
|
Cost of Revenue
|
-194.5m
EUR
|
Gross Profit
|
60.1m
EUR
|
Operating Expenses
|
-41.1m
EUR
|
Operating Income
|
19m
EUR
|
Other Expenses
|
-7m
EUR
|
Net Income
|
12m
EUR
|
Free Cash Flow Analysis
Stratec SE
What is Free Cash Flow?
SBS Profitability Score
Profitability Due Diligence
Stratec SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Stratec SE's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
SBS Solvency Score
Solvency Due Diligence
Stratec SE's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Stratec SE's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SBS Price Targets Summary
Stratec SE
According to Wall Street analysts, the average 1-year price target for SBS is 53.27 EUR with a low forecast of 40.4 EUR and a high forecast of 81.9 EUR.
Shareholder Return
SBS Price
Stratec SE
Average Annual Return | 18.58% |
Standard Deviation of Annual Returns | 54.41% |
Max Drawdown | -74% |
Market Capitalization | 488.7m EUR |
Shares Outstanding | 12 155 944 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. The company is headquartered in Birkenfeld, Baden-Wuerttemberg and currently employs 1,398 full-time employees. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
Contact
IPO
Employees
Officers
The intrinsic value of one SBS stock under the Base Case scenario is 71.24 EUR.
Compared to the current market price of 40.2 EUR, Stratec SE is Undervalued by 44%.